ACTG news release
CHAPEL HILL, N.C., June 03, 2026 — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the recent opening of study A5413, a study that expands upon the network’s commitment to finding a cure for HIV by looking at the HIV reservoir in people living with HIV who are on antiretroviral therapy (ART). A5413 is a randomized, double-blind, placebo-controlled clinical trial evaluating the safety, tolerability, and impact on the HIV reservoir of oral dasatinib among people living with HIV whose viral load is controlled by taking ART.
A5413 will enroll 14 participants aged 18 years and above who have been taking ART continuously for at least four years and have been virally suppressed for at least three years. Participants will be randomized to either receive 100 mg of oral dasatinib daily (eight participants) or matched placebo (six participants) for 12 weeks, and then followed for 24 weeks.
Read the full news release here.
Source : GLOBE NEWSWIRE
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.